Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population

Journal of Korean Medical Science

Volumn 28, Issue 4, 2013, Pages 534-541

  Min, Hye Sook ^a   Lee, Chul ^a   Jung, Kyeong Cheon ^a  

^a Seoul National University   (South Korea)

Author keywords

Histological variant; Immunohistochemistry; Papillary; PTEN; S100A4; Thyroid carcinoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GALECTIN 3; HBME 1 ANTIGEN; HBME-1 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S 100; S100A4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASIAN; EXON; FEMALE; GENETICS; HISTOLOGICAL VARIANT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOLOGY; PTEN; S100A4; SOUTH KOREA; THYROID CARCINOMA, PAPILLARY; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

HISTOLOGICAL VARIANT; IMMUNOHISTOCHEMISTRY; PTEN; S100A4; THYROID CARCINOMA, PAPILLARY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; REPUBLIC OF KOREA; S100 PROTEINS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84877852476     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.4.534     Document Type: Article

References (29)

1. Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 2000; 88: 1902-8.
2. Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, Kihara M, Miyauchi A. Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 2008; 99: 1908-15.
3. Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 2010; 20: 153-8.
4. LiVolsi VA. Papillary carcinoma tall cell variant (TCV): a review. Endocr Pathol 2010; 21: 12-5.
5. Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid 2008; 18: 1179-81.
6. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A, Weryha G. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 656-8.
7. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 2005; 93: 1277-84.
8. Min HS, Choe G, Kim SW, Park YJ, Park do J, Youn YK, Park SH, Cho BY, Park SY. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 2008; 21: 748-55.
9. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathol Int 2005; 55: 757-65.
10. Landriscina M, Pannone G, Piscazzi A, Toti P, Fabiano A, Tortorella S, Occhini R, Ambrosi A, Bufo P, Cignarelli M. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid 2011; 21: 1227-34.
11. Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Bockisch A, Otterbach F. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 2005; 44: 179-82, 184.
12. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 2007; 92: 2387-90.
13. Alvarez-Nuñez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E, de Leiva A, Matias-Guiu X; Thyroid Neoplasia Study Group. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 2006; 16: 17-23.
14. Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, Patsouris E, Tseleni-Balafouta S. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol 2010; 21: 90-100.
15. Ito Y, Hirokawa M, Uruno T, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A. Prevalence and biological behaviour of variants of papillary thyroid carcinoma: experience at a single institute. Pathology 2008; 40: 617-22.
16. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A. S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology 2004; 67: 397-402.
17. De Araujo-Filho VJ, Alves VA, de Castro IV, Lourenço SV, Cernea CR, Brandão LG, Ferraz AR. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid 2009; 19: 1233-7.
18. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005; 18: 48-57.
19. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010; 21: 80-9.
20. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 2010; 5: 9.
21. Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, Yoon SK, Son YI, Chung JH, Oh YL. The cytological, clinical, and pathological features of the cribriform- morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid 2009; 19: 905-13.
22. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 1814-8.
23. Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, Heldin NE, Grimelius L. EGF-receptors in human normal and pathological thyroid tissue. Histopathology 1996; 28: 221-7.
24. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000; 156: 1693-700.
25. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
26. Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, Bae JS, Choi YJ. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid 2012; 22: 791-7.
27. Kim KH, Suh KS, Kang DW, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 2005; 55: 540-5.
28. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 2006; 91: 2414-23.
29. Bhaijee F, Nikiforov YE. Molecular analysis of thyroid tumors. Endocr Pathol 2011; 22: 126-33.